The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II cluster study of single agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced non-small cell lung cancer (NSCLC).
Qing Zhou
No relevant relationships to disclose
Xu-Chao Zhang
No relevant relationships to disclose
Bin Peng
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Xiaolu Yu
No relevant relationships to disclose
Mikhail Akimov
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Barbara Lynn Weber
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Yi-Long Wu
Honoraria - AstraZeneca; Lilly; Roche